Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−52.60 USD
−257.26 M USD
26.00 M USD
9.21 M
About Cartesian Therapeutics, Inc.
Sector
Industry
CEO
Carsten Brunn
Website
Headquarters
Gaithersburg
FIGI
BBG001J19Q25
Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of RNAC is 18.87 USD — it has increased by 13.54% in the past 24 hours. Watch Cartesian Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cartesian Therapeutics, Inc. stocks are traded under the ticker RNAC.
RNAC stock has risen by 11.00% compared to the previous week, the month change is a −13.84% fall, over the last year Cartesian Therapeutics, Inc. has showed a −46.24% decrease.
We've gathered analysts' opinions on Cartesian Therapeutics, Inc. future price: according to them, RNAC price has a max estimate of 41.00 USD and a min estimate of 39.00 USD. Watch RNAC chart and read a more detailed Cartesian Therapeutics, Inc. stock forecast: see what analysts think of Cartesian Therapeutics, Inc. and suggest that you do with its stocks.
RNAC reached its all-time high on Nov 28, 2016 with the price of 839.99 USD, and its all-time low was 11.67 USD and was reached on Apr 8, 2024. View more price dynamics on RNAC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
RNAC stock is 15.42% volatile and has beta coefficient of 1.92. Track Cartesian Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Cartesian Therapeutics, Inc. there?
Today Cartesian Therapeutics, Inc. has the market capitalization of 479.58 M, it has decreased by −4.10% over the last week.
Yes, you can track Cartesian Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Cartesian Therapeutics, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
RNAC earnings for the last quarter are −1.13 USD per share, whereas the estimation was −0.80 USD resulting in a −40.96% surprise. The estimated earnings for the next quarter are −0.80 USD per share. See more details about Cartesian Therapeutics, Inc. earnings.
Cartesian Therapeutics, Inc. revenue for the last quarter amounts to 387.00 K USD, despite the estimated figure of 1.25 M USD. In the next quarter, revenue is expected to reach 160.00 K USD.
RNAC net income for the last quarter is −24.18 M USD, while the quarter before that showed 9.63 M USD of net income which accounts for −351.17% change. Track more Cartesian Therapeutics, Inc. financial stats to get the full picture.
No, RNAC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 23, 2024, the company has 38.00 employees. See our rating of the largest employees — is Cartesian Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Cartesian Therapeutics, Inc. EBITDA is −51.78 M USD, and current EBITDA margin is −326.35%. See more stats in Cartesian Therapeutics, Inc. financial statements.
Like other stocks, RNAC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cartesian Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cartesian Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cartesian Therapeutics, Inc. stock shows the sell signal. See more of Cartesian Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.